NewLimit, a biotechnology startup focused on extending healthy human lifespan through cell reprogramming, has raised US$130 million in a series B funding round.

NewLimit was founded over four years ago by Coinbase CEO Brian Armstrong, former GV partner Blake Byers, and stem cell researcher Jacob Kimmel.

The company reports progress in developing treatments aimed at restoring youthful characteristics to aged cells.

The round was led by Kleiner Perkins and included investors Nat Friedman, Daniel Gross, and Khosla Ventures, alongside returning backers Founders Fund, Elad Gil, Garry Tan, and Patrick Collison.

According to Byers, the company has identified three prototype medicines for reprogramming liver cells. These prototypes have shown potential to improve the cells’ ability to process fat and alcohol in laboratory experiments.

🔗 Source: TechCrunch

🧠 Food for thought

1️⃣ Longevity science has transformed from fringe research to mainstream biotech investment

The shift in longevity science’s credibility is reflected in its dramatic funding growth, from minimal investment before 2016 to $850 million in 2018 alone, an increase of over 160% from 2017’s $324 million1.

This surge correlates directly with scientific advancements, particularly the identification of the nine biological hallmarks of aging in a landmark 2013 paper published in Cell, which provided a framework for targeting aging mechanisms1.

The legitimization of aging research has been further reinforced by institutional support, including the establishment of the National Institute on Aging in 1974 and the continued development of dedicated aging research departments at major research institutions2.

Today’s landscape features not just biotech entrepreneurs but high-profile tech billionaires like Jeff Bezos (Altos Labs), Sam Altman (Retro Biosciences), and Brian Armstrong (NewLimit), signaling that longevity has crossed the threshold from speculative science to serious business opportunity34.

The market is now projected to reach $600 billion by 2025 according to industry analysts, representing one of the fastest-growing segments within biotechnology5.

2️⃣ AI-driven drug discovery creates competitive advantages in aging research

NewLimit’s “lab in a loop” approach, where AI models simulate experiments before selecting the most promising ones for laboratory validation, exemplifies a crucial efficiency innovation in a field where traditional drug discovery is notoriously slow and expensive.

This integration of AI is becoming standard among leading longevity companies, with Insilico Medicine raising over $400 million specifically to apply artificial intelligence to discover drugs for age-related conditions4.